Metabolic syndrome | Nature Reviews Disease Primers
Reaven, G. M. Why syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 1, 9–14 (2005).
Google Scholar
Despres, J. P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881–887 (2006). A paper outlining that the most prevalent form of the metabolic syndrome is found among individuals with excess visceral adipose tissue and ectopic fat.
Google Scholar
Despres, J. P. et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28, 1039–1049 (2008).
Google Scholar
Reaven, G. M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988).
Google Scholar
Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998).
Google Scholar
Balkau, B. & Charles, M. A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16, 442–443 (1999).
Google Scholar
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
Google Scholar
Hagberg, C. E. & Spalding, K. L. White adipocyte dysfunction and obesity-associated pathologies in humans. Nat. Rev. Mol. Cell Biol. 25, 270–289 (2024). An update on the function and roles of white adipocytes in human diseases.
Google Scholar
Grundy, S. M. et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004).
Google Scholar
Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009). The most contemporary definition of the metabolic syndrome and rationale for the definition.
Google Scholar
Sperling, L. S. et al. The Cardiometabolic Health Alliance: working toward a new care model for the metabolic syndrome. J. Am. Coll. Cardiol. 66, 1050–1067 (2015). A discussion of the strategy and intervention for the metabolic syndrome from a joint cardiovascular and endocrinological perspective.
Google Scholar
Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636–1664 (2023).
Google Scholar
Alberti, K. G., Zimmet, P. & Shaw, J. The metabolic syndrome – a new worldwide definition. Lancet 366, 1059–1062 (2005).
Google Scholar
Bloomgarden, Z. T. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 26, 1297–1303 (2003).
Google Scholar
Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
Google Scholar
Liang, X., Or, B., Tsoi, M. F., Cheung, C. L. & Cheung, B. M. Y. Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011-18. Postgrad. Med. J. 99, 985–992 (2023).
Google Scholar
Dev, R. et al. Impact of sex and gender on metabolic syndrome in adults: a retrospective cohort study from the Canadian Primary Care Sentinel Surveillance Network. Can. J. Diabetes 99, 36–43.e2 (2023).
Perez-Castro, E., Godinez-Jaimes, F., Vazquez-Medina, M. U., Ocharan-Hernandez, M. E. & Vargas-De-Leon, C. Derivation and validation of sex-specific continuous metabolic syndrome scores for the Mexican adult population. Sci. Rep. 12, 9659 (2022).
Google Scholar
Vishram, J. K. et al. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS ONE 9, e107294 (2014).
Google Scholar
Cen, M. et al. Associations between metabolic syndrome and anxiety, and the mediating role of inflammation: findings from the UK Biobank. Brain Behav. Immun. 116, 1–9 (2023).
Google Scholar
Yamazaki, Y. et al. Usefulness of new criteria for metabolic syndrome optimized for prediction of cardiovascular diseases in Japanese. J. Atheroscler. Thromb. 31, 382–395 (2024).
Google Scholar
Park, D. et al. 20-year trends in metabolic syndrome among Korean adults from 2001 to 2020. JACC Asia 3, 491–502 (2023).
Google Scholar
Yang, S. et al. Development and validation of an age-sex-ethnicity-specific metabolic syndrome score in the Chinese adults. Nat. Commun. 14, 6988 (2023).
Google Scholar
Ramachandran, A., Snehalatha, C., Satyavani, K., Sivasankari, S. & Vijay, V. Metabolic syndrome in urban Asian Indian adults – a population study using modified ATP III criteria. Diabetes Res. Clin. Pract. 60, 199–204 (2003).
Google Scholar
Krishnamoorthy, Y. et al. Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis. PLoS ONE 15, e0240971 (2020).
Google Scholar
Bowo-Ngandji, A. et al. Prevalence of the metabolic syndrome in African populations: a systematic review and meta-analysis. PLoS ONE 18, e0289155 (2023).
Google Scholar
Asgedom, Y. S. et al. Prevalence of metabolic syndrome among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis. Sci. Rep. 14, 11709 (2024).
Google Scholar
Tagi, V. M., Samvelyan, S. & Chiarelli, F. Treatment of metabolic syndrome in children. Horm. Res. Paediatr. 93, 215–225 (2020).
Google Scholar
Reisinger, C., Nkeh-Chungag, B. N., Fredriksen, P. M. & Goswami, N. The prevalence of pediatric metabolic syndrome – a critical look on the discrepancies between definitions and its clinical importance. Int. J. Obes. 45, 12–24 (2021). A critical discussion of issues relevant to the metabolic sydrome in the paediatric population.
Google Scholar
Noubiap, J. J. et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child. Adolesc. Health 6, 158–170 (2022).
Google Scholar
Messiah, S. E. et al. Prevalence of the metabolic syndrome by household food insecurity status in the United States adolescent population, 2001-2020: a cross-sectional study. Am. J. Clin. Nutr. 119, 354–361 (2023).
Google Scholar
Choi, J. E. et al. Increase of prevalence of obesity and metabolic syndrome in children and adolescents in Korea during the COVID-19 pandemic: a cross-sectional study using the KNHANES. Children 10, 1105 (2023).
Google Scholar
Varhlunchungi, V. et al. Metabolic syndrome among adolescents aged 10–19 years in India: a systematic review and meta-analysis. Cureus 15, e48636 (2023).
Google Scholar
Cook, S., Weitzman, M., Auinger, P., Nguyen, M. & Dietz, W. H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med. 157, 821–827 (2003).
Google Scholar
Cheng, X. et al. Association between sedentary behavior, screen time and metabolic syndrome among Chinese children and adolescents. BMC Public. Health 24, 1715 (2024).
Google Scholar
Tchernof, A. & Despres, J. P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 93, 359–404 (2013). A comprehensive review of the role of excess visceral adiposity as a key driver of cardiometabolic risk.
Google Scholar
Neeland, I. J. et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 21, E439–E447 (2012).
Yaskolka Meir, A. et al. Intrahepatic fat, abdominal adipose tissues, and metabolic state: magnetic resonance imaging study. Diabetes Metab. Res. Rev. 33, e2888 (2017).
Saponaro, C. et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver Int. 42, 2418–2427 (2022). A paper showing that individuals with non-alcoholic steatohepatitis have increased VAT that is associated with insulin resistance in liver, muscle and adipose tissue, increased lipolysis and decreased adiponectin levels.
Google Scholar
Gepner, Y. et al. Intramyocellular triacylglycerol accumulation across weight loss strategies; sub-study of the CENTRAL trial. PLoS ONE 12, e0188431 (2017).
Google Scholar
Choe, H. J., Chang, W., Bluher, M., Heymsfield, S. B. & Lim, S. Independent association of thigh muscle fat density with vascular events in Korean adults. Cardiovasc. Diabetol. 23, 44 (2024).
Google Scholar
Roh, E. et al. Comparison of pancreatic volume and fat amount linked with glucose homeostasis between healthy Caucasians and Koreans. Diabetes Obes. Metab. 20, 2642–2652 (2018).
Google Scholar
Zelicha, H. et al. Changes of renal sinus fat and renal parenchymal fat during an 18-month randomized weight loss trial. Clin. Nutr. 37, 1145–1153 (2018).
Google Scholar
Kim, T. H. et al. Pericardial fat amount is an independent risk factor of coronary artery stenosis assessed by multidetector-row computed tomography: the Korean Atherosclerosis Study 2. Obesity 19, 1028–1034 (2011).
Google Scholar
Chin, J. F. et al. Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity. Eur. J. Heart Fail. 25, 1936–1943 (2023).
Google Scholar
Chen, O. et al. Correlation between pericardial, mediastinal, and intrathoracic fat volumes with the presence and severity of coronary artery disease, metabolic syndrome, and cardiac risk factors. Eur. Heart J. Cardiovasc. Imaging 16, 37–46 (2015).
Google Scholar
Tsaban, G. et al. Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss. Am. J. Clin. Nutr. 106, 984–995 (2017).
Google Scholar
Sironi, A. M. et al. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet. Med. 29, 622–627 (2012).
Google Scholar
Piche, M. E., Tchernof, A. & Despres, J. P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ. Res. 126, 1477–1500 (2020). A proposal to move discussions from obesity as a single disorder to obesities (that is, obesity phenotypes).
Google Scholar
Bilson, J. et al. Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD. Metabolism 151, 155759 (2023).
Google Scholar
Michaud, A. et al. Relevance of omental pericellular adipose tissue collagen in the pathophysiology of human abdominal obesity and related cardiometabolic risk. Int. J. Obes. 40, 1823–1831 (2016).
Google Scholar
Laforest, S., Labrecque, J., Michaud, A., Cianflone, K. & Tchernof, A. Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. Crit. Rev. Clin. Lab. Sci. 52, 301–313 (2015).
Google Scholar
Michaud, A., Drolet, R., Noel, S., Paris, G. & Tchernof, A. Visceral fat accumulation is an indicator of adipose tissue macrophage infiltration in women. Metabolism 61, 689–698 (2012).
Google Scholar
Harman-Boehm, I. et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. 92, 2240–2247 (2007).
Google Scholar
Rosendo-Silva, D. et al. Clinical and molecular profiling of human visceral adipose tissue reveals impairment of vascular architecture and remodeling as an early hallmark of dysfunction. Metabolism 153, 155788 (2024).
Google Scholar
Rosso, C. et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J. Hepatol. 71, 1012–1021 (2019). Altered adipose tissue metabolism is associated with macrophage activity in MASLD, independent of obesity and diabetes mellitus, probably due to FFA spillover from adipose tissue.
Google Scholar
Bouchard, C. et al. The response to long-term overfeeding in identical twins. N. Engl. J. Med. 322, 1477–1482 (1990). A seminal intervention study documenting that susceptibility to visceral versus subcutaneous adipose tissue deposition has a genetic basis.
Google Scholar
Thomas, D. G., Wei, Y. & Tall, A. R. Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study. J. Lipid Res. 62, 100044 (2021).
Google Scholar
He, Q. et al. Genetic insights into the risk of metabolic syndrome and its components on stroke and its subtypes: bidirectional Mendelian randomization. J. Cereb. Blood Flow. Metab. 43, 126–137 (2023).
Google Scholar
Xia, L. et al. A Mendelian randomization study between metabolic syndrome and its components with prostate cancer. Sci. Rep. 14, 14338 (2024).
Google Scholar
Gao, X. et al. Genetic evidence for the causal relations between metabolic syndrome and psychiatric disorders: a Mendelian randomization study. Transl. Psychiatry 14, 46 (2024).
Google Scholar
Marc, J. Genetic succeptibility to metabolic syndrome. EJIFCC 18, 7–14 (2007).
Google Scholar
McCarthy, J. J. et al. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum. Genet. 114, 87–98 (2003).
Google Scholar
Xiao, Z. & Liu, H. The estrogen receptor and metabolism. Womens Health 20, 17455057241227362 (2024).
Tchernof, A. et al. Androgens and the regulation of adiposity and body fat distribution in humans. Compr. Physiol. 8, 1253–1290 (2018).
Google Scholar
Starcke, S. & Vollmer, G. Is there an estrogenic component in the metabolic syndrome. Genes. Nutr. 1, 177–188 (2006).
Google Scholar
Cherubini, A. et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat. Med. 29, 2643–2655 (2023).
Google Scholar
White, U. & Ravussin, E. Dynamics of adipose tissue turnover in human metabolic health and disease. Diabetologia 62, 17–23 (2019).
Google Scholar
Lim, S. & Meigs, J. B. Links between ectopic fat and vascular disease in humans. Arterioscler. Thromb. Vasc. Biol. 34, 1820–1826 (2014).
Google Scholar
Rosito, G. A. et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 117, 605–613 (2008).
Google Scholar
Ding, J. et al. Association between non-subcutaneous adiposity and calcified coronary plaque: a substudy of the Multi-Ethnic Study of Atherosclerosis. Am. J. Clin. Nutr. 88, 645–650 (2008).
Google Scholar
Wu, Y., Zhang, A., Hamilton, D. J. & Deng, T. Epicardial fat in the maintenance of cardiovascular health. Methodist. Debakey Cardiovasc. J. 13, 20–24 (2017).
Google Scholar
Thanassoulis, G. et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ. Arrhythm. Electrophysiol. 3, 345–350 (2010).
Google Scholar
Lamacchia, O. et al. Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients. Nephrol. Dial. Transpl. 26, 892–898 (2011).
Google Scholar
Guo, X. L., Wang, J. W., Tu, M. & Wang, W. Perirenal fat thickness as a superior obesity-related marker of subclinical carotid atherosclerosis in type 2 diabetes mellitus. Front. Endocrinol. 14, 1276789 (2023).
Google Scholar
Bosy-Westphal, A., Braun, W., Albrecht, V. & Muller, M. J. Determinants of ectopic liver fat in metabolic disease. Eur. J. Clin. Nutr. 73, 209–214 (2019).
Google Scholar
Montastier, E. et al. Increased postprandial nonesterified fatty acid efflux from adipose tissue in prediabetes is offset by enhanced dietary fatty acid adipose trapping. Am. J. Physiol. Endocrinol. Metab. 320, E1093–E1106 (2021).
Google Scholar
Couillard, C. et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 47, 953–960 (1998).
Google Scholar
Carpentier, A. C., Labbé, S. M., Grenier-Larouche, T. & Noll, C. Abnormal dietary fatty acid metabolic partitioning in insulin resistance and type 2 diabetes. Clin. Lipidol. 6, 703–716 (2013).
Google Scholar
Spalding, K. L. et al. Dynamics of fat cell turnover in humans. Nature 453, 783–787 (2008).
Google Scholar
Virtue, S. & Vidal-Puig, A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome – an allostatic perspective. Biochim. Biophys. Acta 1801, 338–349 (2010).
Google Scholar
Arner, E. et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 59, 105–109 (2010).
Google Scholar
Iacobini, C., Vitale, M., Haxhi, J., Menini, S. & Pugliese, G. Impaired remodeling of white adipose tissue in obesity and aging: from defective adipogenesis to adipose organ dysfunction. Cells 13, 763 (2024).
Google Scholar
Lessard, J. et al. Low abdominal subcutaneous preadipocyte adipogenesis is associated with visceral obesity, visceral adipocyte hypertrophy, and a dysmetabolic state. Adipocyte 3, 197–205 (2014).
Google Scholar
Gastaldelli, A. et al. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int. 41, 2659–2670 (2021).
Google Scholar
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A. & Smith, U. Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity. Physiol. Rev. 98, 1911–1941 (2018). A comprehensive review of the role of impaired adipogenesis as a primary defect leading to increased cardiometabolic risk.
Google Scholar
Gustafson, B., Nerstedt, A. & Smith, U. Reduced subcutaneous adipogenesis in human hypertrophic obesity is linked to senescent precursor cells. Nat. Commun. 10, 2757 (2019).
Google Scholar
Rouault, C. et al. Senescence-associated β-galactosidase in subcutaneous adipose tissue associates with altered glycaemic status and truncal fat in severe obesity. Diabetologia 64, 240–254 (2021).
Google Scholar
Smith, U., Li, Q., Ryden, M. & Spalding, K. L. Cellular senescence and its role in white adipose tissue. Int. J. Obes. 45, 934–943 (2021).
Google Scholar
Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542–1556 (2023). The new definition of MASLD, which now includes steatosis plus at least one feature of the metabolic syndrome, especially steatosis with increased waist circumference.
Google Scholar
Liu, J. et al. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler. Thromb. Vasc. Biol. 31, 2715–2722 (2011).
Google Scholar
Chen, Y.-l et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 21, 212 (2021).
Google Scholar
Adiels, M. et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49, 755–765 (2006).
Google Scholar
Hodson, L. et al. The contribution of splanchnic fat to VLDL triglyceride is greater in insulin-resistant than insulin-sensitive men and women: studies in the postprandial state. Diabetes 56, 2433–2441 (2007).
Google Scholar
Boden, G., Chen, X., Capulong, E. & Mozzoli, M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 50, 810–816 (2001).
Google Scholar
Stefan, N. et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57, 2762–2767 (2008).
Google Scholar
Peter, A. et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am. J. Physiol. Endocrinol. Metab. 314, E266–E273 (2018).
Google Scholar
Mindur, J. E. & Swirski, F. K. Growth factors as immunotherapeutic targets in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 39, 1275–1287 (2019).
Google Scholar
Gaggini, M. et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5, 1544–1560 (2013).
Google Scholar
Tejani, S. et al. Cardiometabolic health outcomes associated with discordant visceral and liver fat phenotypes: insights from the Dallas Heart Study and UK Biobank. Mayo Clin. Proc. 97, 225–237 (2022).
Google Scholar
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G. & Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 65, 589–600 (2016).
Google Scholar
Lauridsen, B. K. et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur. Heart J. 39, 385–393 (2018).
Google Scholar
Klein, S., Gastaldelli, A., Yki-Jarvinen, H. & Scherer, P. E. Why does obesity cause diabetes? Cell Metab. 34, 11–20 (2022). This review discusses the complex cellular and physiological mechanisms responsible for the link between obesity and T2DM, which involve adiposity-induced alterations in β-cell function, adipose tissue biology and multi-organ insulin resistance.
Google Scholar
DeFronzo, R. A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53, 1270–1287 (2010).
Google Scholar
Brehm, A. et al. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes 55, 136–140 (2006).
Google Scholar
Belfort, R. et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54, 1640–1648 (2005).
Google Scholar
Gastaldelli, A. et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496–506 (2007).
Google Scholar
Masoodi, M. et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat. Rev. Gastroenterol. Hepatol. 18, 835–856 (2021).
Google Scholar
Magkos, F. et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142, 1444–1446.e2 (2012).
Google Scholar
Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64, 1167–1175 (2016).
Google Scholar
Samuel, V. T. & Shulman, G. I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12–22 (2016).
Google Scholar
Stratford, S., Hoehn, K. L., Liu, F. & Summers, S. A. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279, 36608–36615 (2004).
Google Scholar
Powell, D. J., Hajduch, E., Kular, G. & Hundal, H. S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCζ-dependent mechanism. Mol. Cell Biol. 23, 7794–7808 (2003).
Google Scholar
Lyu, K. et al. A membrane-bound diacylglycerol species induces PKCε-mediated hepatic insulin resistance. Cell Metab. 32, 654–664.e5 (2020).
Google Scholar
Hilvo, M. et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur. Heart J. 41, 371–380 (2020).
Google Scholar
Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011).
Google Scholar
Holland, W. L. et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17, 55–63 (2011).
Google Scholar
Holland, W. L. et al. Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol. Metab. 6, 267–275 (2017).
Google Scholar
Vijay, J. et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat. Metab. 2, 97–109 (2020).
Google Scholar
Lin, D., Chun, T. H. & Kang, L. Adipose extracellular matrix remodelling in obesity and insulin resistance. Biochem. Pharmacol. 119, 8–16 (2016).
Google Scholar
Ruiz-Ojeda, F. J., Mendez-Gutierrez, A., Aguilera, C. M. & Plaza-Diaz, J. Extracellular matrix remodeling of adipose tissue in obesity and metabolic diseases. Int. J. Mol. Sci. 20, 4888 (2019).
Google Scholar
Divoux, A. et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 59, 2817–2825 (2010).
Google Scholar
Divoux, A. & Clement, K. Architecture and the extracellular matrix: the still unappreciated components of the adipose tissue. Obes. Rev. 12, e494–e503 (2011).
Google Scholar
Antoniades, C. et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur. Heart J. 44, 3827–3844 (2023).
Google Scholar
Sun, J. Y., Su, Z., Yang, J., Sun, W. & Kong, X. The potential mechanisms underlying the modulating effect of perirenal adipose tissue on hypertension: physical compression, paracrine, and neurogenic regulation. Life Sci. 342, 122511 (2024).
Google Scholar
Antoniades, C., Antonopoulos, A. S. & Deanfield, J. Imaging residual inflammatory cardiovascular risk. Eur. Heart J. 41, 748–758 (2020).
Google Scholar
Hall, J. E. et al. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Cardiovasc. Res. 117, 1859–1876 (2021).
Google Scholar
Gaba, P., Gersh, B. J., Muller, J., Narula, J. & Stone, G. W. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat. Rev. Cardiol. 20, 181–196 (2023).
Google Scholar
Cuspidi, C. et al. Nondipping pattern and carotid atherosclerosis: a systematic review and meta-analysis. J. Hypertens. 34, 385–391 (2016).
Google Scholar
Li, M. et al. The pathophysiological associations between obesity, NAFLD, and atherosclerotic cardiovascular diseases. Horm. Metab. Res. (2024).
Google Scholar
Gallo, G. & Savoia, C. New insights into endothelial dysfunction in cardiometabolic diseases: potential mechanisms and clinical implications. Int. J. Mol. Sci. 25, 2973 (2024).
Google Scholar
Luciani, L., Pedrelli, M. & Parini, P. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes. Atherosclerosis 394, 117545 (2024).
Google Scholar
Moriyama, K. The association between the triglyceride to high-density lipoprotein cholesterol ratio and low-density lipoprotein subclasses. Intern. Med. 59, 2661–2669 (2020).
Google Scholar
Silveira Rossi, J. L. et al. Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes Metab. Res. Rev. 38, e3502 (2022).
Google Scholar
Masenga, S. K., Kabwe, L. S., Chakulya, M. & Kirabo, A. Mechanisms of oxidative stress in metabolic syndrome. Int. J. Mol. Sci. 24, 7898 (2023).
Google Scholar
Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).
Google Scholar
Rangaswami, J. et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139, e840–e878 (2019).
Google Scholar
Einhorn, D. et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237–252 (2003).
Google Scholar
Neeland, I. J. et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 7, 715–725 (2019). A key position statement describing the link between visceral adipose tissue and ectopic fat, and cardiometabolic disease.
Google Scholar
Gami, A. S. et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49, 403–414 (2007).
Google Scholar
Neeland, I. J., Yokoo, T., Leinhard, O. D. & Lavie, C. J. 21st century advances in multimodality imaging of obesity for care of the cardiovascular patient. JACC Cardiovasc. Imaging 14, 482–494 (2021).
Google Scholar
van Walree, E. S. et al. Disentangling genetic risks for metabolic syndrome. Diabetes 71, 2447–2457 (2022).
Google Scholar
Hsu, N. W. et al. Building a model for predicting metabolic syndrome using artificial intelligence based on an investigation of whole-genome sequencing. J. Transl. Med. 20, 190 (2022).
Google Scholar
Benmohammed, K., Valensi, P., Omri, N., Al Masry, Z. & Zerhouni, N. Metabolic syndrome screening in adolescents: new scores AI_METS based on artificial intelligence techniques. Nutr. Metab. Cardiovasc. Dis. 32, 2890–2899 (2022).
Google Scholar
Neeland, I. J., Poirier, P. & Despres, J. P. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 137, 1391–1406 (2018). A review article describing the heterogeneous manifestations and health complications related to obesity.
Google Scholar
Despres, J. P. et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler. Thromb. Vasc. Biol. 20, 1932–1938 (2000).
Google Scholar
Warburton, D. E., Charlesworth, S., Ivey, A., Nettlefold, L. & Bredin, S. S. A systematic review of the evidence for Canada’s Physical Activity Guidelines for Adults. Int. J. Behav. Nutr. Phys. Act. 7, 39 (2010).
Google Scholar
Broekhuizen, L. N. et al. Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. Eur. J. Cardiovasc. Prev. Rehabil. 18, 209–217 (2011).
Google Scholar
Eilat-Adar, S. et al. Dietary patterns and their association with cardiovascular risk factors in a population undergoing lifestyle changes: the Strong Heart Study. Nutr. Metab. Cardiovasc. Dis. 23, 528–535 (2013).
Google Scholar
Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279–1290 (2013).
Google Scholar
Mozaffarian, D., Appel, L. J. & Van Horn, L. Components of a cardioprotective diet: new insights. Circulation 123, 2870–2891 (2011).
Google Scholar
Alexander, C. M. et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210–1214 (2003).
Google Scholar
Rubino, F. et al. Lancet Diabetes & Endocrinology Commission on the definition and diagnosis of clinical obesity. Lancet Diabetes Endocrinol. 11, 226–228 (2023).
Google Scholar
Busetto, L. et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat. Med. 20, 2395–2399 (2024).
Google Scholar
Rao, S. et al. Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials. Mayo Clin. Proc. 94, 211–224 (2019).
Google Scholar
Neeland, I. J. et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 9, 595–605 (2021). The first randomized clinical trial to describe the effects of GLP1 receptor agonists on VAT and ectopic fat in individuals without diabetes mellitus.
Google Scholar
Meyer-Gerspach, A. C. et al. Quantification of liver, subcutaneous, and visceral adipose tissues by MRI before and after bariatric surgery. Obes. Surg. 29, 2795–2805 (2019).
Google Scholar
Hanipah, Z. N. & Schauer, P. R. Bariatric surgery as a long-term treatment for type 2 diabetes/metabolic syndrome. Annu. Rev. Med. 71, 1–15 (2020).
Google Scholar
Picot, J. et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol. Assess. (2009).
Yu, W., Chen, J., Fan, L., Yan, C. & Zhu, L. Cost-effectiveness of laparoscopic sleeve gastrectomy for Chinese patients. Obes. Surg. 34, 2828–2834 (2024).
Google Scholar
Gallagher, C., Corl, A. & Dietz, W. H. Weight can’t wait: a guide to discussing obesity and organizing treatment in the primary care setting. Obesity 29, 821–824 (2021).
Google Scholar
Wadden, T. A., Tronieri, J. S. & Butryn, M. L. Lifestyle modification approaches for the treatment of obesity in adults. Am. Psychol. 75, 235–251 (2020).
Google Scholar
Alamuddin, N. & Wadden, T. A. Behavioral treatment of the patient with obesity. Endocrinol. Metab. Clin. North. Am. 45, 565–580 (2016).
Google Scholar
Lichtenstein, A. H. et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation 144, e472–e487 (2021).
Google Scholar
Jensen, M. D. et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129, S102–S138 (2014).
Google Scholar
Wewege, M. A., Thom, J. M., Rye, K. A. & Parmenter, B. J. Aerobic, resistance or combined training: a systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome. Atherosclerosis 274, 162–171 (2018).
Google Scholar
Chomiuk, T., Niezgoda, N., Mamcarz, A. & Sliz, D. Physical activity in metabolic syndrome. Front. Physiol. 15, 1365761 (2024).
Google Scholar
Barone Gibbs, B. et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how?: A scientific statement from the American Heart Association. Hypertension 78, e26–e37 (2021).
Google Scholar
Powell-Wiley, T. M. et al. Social determinants of cardiovascular disease. Circ. Res. 130, 782–799 (2022).
Google Scholar
Gaede, P., Lund-Andersen, H., Parving, H. H. & Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).
Google Scholar
Cornier, M. A. et al. The metabolic syndrome. Endocr. Rev. 29, 777–822 (2008).
Google Scholar
Shang, Y. et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care 47, 978–985 (2024).
Google Scholar
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
Google Scholar
Jang, H. et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern. Med. 184, 375–383 (2024).
Google Scholar
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R. & Davies, M. J. Type 2 diabetes. Lancet 400, 1803–1820 (2022).
Google Scholar
Moon, J. S. et al. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol. Metab. 33, 424–442 (2022).
Google Scholar
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788–1801 (2022).
Google Scholar
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).
Google Scholar
Campbell, J. E. et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 35, 1519–1529 (2023).
Google Scholar
Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143–155 (2021).
Google Scholar
Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N. Engl. J. Med. 389, 514–526 (2023).
Google Scholar
Wright, J. T. Jr et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
Google Scholar
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation 140, e596–e646 (2019).
Google Scholar
Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11–22 (2019).
Google Scholar
Gaziano, J. M. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392, 1036–1046 (2018).
Google Scholar
McNeil, J. J. et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N. Engl. J. Med. 379, 1509–1518 (2018).
Google Scholar
Bowman, L. et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529–1539 (2018).
Google Scholar
Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Collaborative Study Group. N. Engl. J. Med. 329, 1456–1462 (1993).
Google Scholar
Herrington, W. G. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023).
Google Scholar
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
Google Scholar
Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
Google Scholar
Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).
Google Scholar
Weihe, P. & Weihrauch-Bluher, S. Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives. Curr. Obes. Rep. 8, 472–479 (2019).
Google Scholar
DeBoer, M D. Assessing and managing the metabolic syndrome in children and adolescents. Nutrients 11, 1788 (2019).
Google Scholar
Ford, E. S. & Li, C. Metabolic syndrome and health-related quality of life among U.S. adults. Ann. Epidemiol. 18, 165–171 (2008).
Google Scholar
Lin, Y. H. et al. Changes in metabolic syndrome affect the health-related quality of life of community-dwelling adults. Sci. Rep. 11, 20267 (2021).
Google Scholar
Tsai, A. G. et al. Metabolic syndrome and health-related quality of life in obese individuals seeking weight reduction. Obesity 16, 59–63 (2008).
Google Scholar
Chen, M. Z., Wong, M. W. K., Lim, J. Y. & Merchant, R. A. Frailty and quality of life in older adults with metabolic syndrome – findings from the Healthy Older People Everyday (HOPE) study. J. Nutr. Health Aging 25, 637–644 (2021).
Google Scholar
Limon, V. M., Lee, M., Gonzalez, B., Choh, A. C. & Czerwinski, S. A. The impact of metabolic syndrome on mental health-related quality of life and depressive symptoms. Qual. Life Res. 29, 2063–2072 (2020).
Google Scholar
Marcos-Delgado, A. et al. Health-related quality of life in individuals with metabolic syndrome: a cross-sectional study. Semergen 46, 524–537 (2020).
Google Scholar
Okosun, I. S., Annor, F., Esuneh, F. & Okoegwale, E. E. Metabolic syndrome and impaired health-related quality of life and in non-Hispanic White, non-Hispanic Blacks and Mexican-American Adults. Diabetes Metab. Syndr. 7, 154–160 (2013).
Google Scholar
Vetter, M. L. et al. Relation of health-related quality of life to metabolic syndrome, obesity, depression and comorbid illnesses. Int. J. Obes. 35, 1087–1094 (2011).
Google Scholar
Wang, Q., Chair, S. Y. & Wong, E. M. The effects of a lifestyle intervention program on physical outcomes, depression, and quality of life in adults with metabolic syndrome: a randomized clinical trial. Int. J. Cardiol. 230, 461–467 (2017).
Google Scholar
Yadav, R., Yadav, R. K., Pandey, R. M. & Upadhyay, A. D. Predictors of health-related quality of life in Indians with metabolic syndrome undergoing randomized controlled trial of yoga-based lifestyle intervention vs dietary intervention. Behav. Med. 47, 151–160 (2021).
Google Scholar
Jeon, J. S. et al. Temporal changes of metabolic indicators and quality of life by a two-day patient education program for metabolic syndrome patients. Int. J. Environ. Res. Public Health 19, 3351 (2022).
Google Scholar
Marcos-Delgado, A., Hernandez-Segura, N., Fernandez-Villa, T., Molina, A. J. & Martin, V. The effect of lifestyle intervention on health-related quality of life in adults with metabolic syndrome: a meta-analysis. Int. J. Environ. Res. Public Health 18, 887 (2021).
Google Scholar
Emery, J. et al. Management of common clinical problems experienced by survivors of cancer. Lancet 399, 1537–1550 (2022).
Google Scholar
Despres, J. P., Carpentier, A. C., Tchernof, A., Neeland, I. J. & Poirier, P. Management of obesity in cardiovascular practice: JACC focus seminar. J. Am. Coll. Cardiol. 78, 513–531 (2021).
Google Scholar
Neeland, I. J. et al. Second-year results from CINEMA: a novel, patient-centered, team-based intervention for patients with type 2 diabetes or prediabetes at high cardiovascular risk. Am. J. Prev. Cardiol. 17, 100630 (2024).
Google Scholar
Ross, R. et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity. Nat. Rev. Endocrinol. 16, 177–189 (2020).
Google Scholar
Gastaldelli, A. & Cusi, K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 1, 312–328 (2019).
Google Scholar
Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6, 903–913 (2021).
Google Scholar
Kim, K. S., Hong, S., Han, K. & Park, C. Y. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ 384, e076388 (2024).
Google Scholar
Fu, C. E. et al. The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Aliment. Pharmacol. Ther. 57, 979–987 (2023).
Google Scholar
Ramo, J. T. et al. Cardiovascular significance and genetics of epicardial and pericardial adiposity. JAMA Cardiol. 9, 418–427 (2024).
Google Scholar
Khan, S. S. et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 148, 1982–2004 (2023). This AHA scientific statement describes the rationale behind the development of the new AHA PREVENT equation for predicting total cardiovascular disease risk in individuals with CKM syndrome.
Google Scholar
Liao, C., Liang, X., Zhang, X. & Li, Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis. PLoS ONE 18, e0289616 (2023).
Google Scholar
Gastaldelli, A. et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10, 393–406 (2022). Clinical trial documenting the effects of dual GIP and GLP1 agonists on visceral adiposity and liver fat content.
Google Scholar
Kadowaki, T. et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 10, 193–206 (2022).
Google Scholar
Ward, Z. J. et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N. Engl. J. Med. 381, 2440–2450 (2019).
Google Scholar
WHO Consultation on Obesity. Obesity: preventing and managing the global epidemic: report of a WHO consultation. WHO Technical Report Series 894 (WHO, 2000).
Zhou, B. F., Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults – study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed. Env. Sci. 15, 83–96 (2002).
Tham, K. W. et al. Obesity in South and Southeast Asia – a new consensus on care and management. Obes. Rev. 24, e13520 (2023).
Google Scholar
Health Promotion Administration, Ministry of Health and Welfare. 2016 Annual Report of Health Administration. Health Promotion Administration (2016).
Misra, A. et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J. Assoc. Physicians India 57, 163–170 (2009).
Google Scholar
Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of, Obesity. New criteria for ‘obesity disease’ in Japan. Circ. J. 66, 987–992 (2002).
Google Scholar
Yang, Y. S. et al. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J. Obes. Metab. Syndr. 31, 169–177 (2022).
Google Scholar
Centre for Health Protection. Body mass index chart. Centre for Health Protection (2019).
Tobias, M., Paul, S. & Turley, M. Tracking the obesity epidemic: New Zealand 1977–2003. Ministry of Health (2004).
Ntuk, U. E., Gill, J. M., Mackay, D. F., Sattar, N. & Pell, J. P. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care 37, 2500–2507 (2014).
Google Scholar
Misra, A., Wasir, J. S. & Vikram, N. K. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition 21, 969–976 (2005).
Google Scholar
Haam, J. H. et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J. Obes. Metab. Syndr. 32, 121–129 (2023).
Google Scholar
link
